Feedback
Interstitial Lung Disease Panel
2013993
Ordering Recommendation

May be useful for evaluation of interstitial lung disease in the context of connective tissue disease.

Mnemonic
ILD PAN
Methodology
Qualitative Immunoprecipitation/Semi-Quantitative Multiplex Bead Assay/Qualitative Immunoblot/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative Immunoturbidimetry
Performed
Mon, Tue, Thu, Fri
Reported
7-15 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Serum Separator Tube (SST). 
Specimen Preparation
Separate from cells ASAP or within 2 hours of collection. Transfer five 1 mL serum aliquots to ARUP Standard Transport Tubes. (Min: 0.5 mL/aliquot) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens. 
Remarks
 
Stability
Ambient: 24 hours; Refrigerated: 1 weeks; Frozen: 1 month 
Reference Interval
Test Number
Components
Reference Interval
2012074SSA 52 and 60 (Ro) (ENA) Antibodies, IgG
ComponentsReference Interval
SSA 52 (Ro) (ENA) Antibody, IgG29 AU/mL or less: Negative
30-40 AU/mL: Equivocal
41 AU/mL or greater: Positive
SSA 60 (Ro) (ENA) Antibody, IgG29 AU/mL or less: Negative
30-40 AU/mL: Equivocal
41 AU/mL or greater: Positive

0050599Scleroderma (Scl-70) (ENA) Antibody, IgG
29 AU/mL or lessNegative
30-40 AU/mLEquivocal
41 AU/mL or greaterPositive

0099592Jo-1 Antibody, IgG
29 AU/mL or lessNegative
30-40 AU/mLEquivocal
41 AU/mL or greaterPositive

 PL-7 (threonyl-tRNA synthetase) AntibodyNegative
 PL-12 (alanyl-tRNA synthetase) AntibodyNegative
 EJ (glycyl-tRNA synthetase) AntibodyNegative
 Ku AntibodyNegative
 SRP (Signal Recognition Particle) AbNegative
 OJ (isoleucyl-tRNA synthetase) AntibodyNegative
2003040PM/Scl-100 Antibody, IgG by ImmunoblotNegative
 MDA5 (CADM-140) AntibodyNegative
 NXP-2 (Nuclear matrix protein-2) AbNegative
0050465Rheumatoid Factor0-14 IU/mL
0055256Cyclic Citrullinated Peptide (CCP) Antibody, IgG
19 Units or lessNegative
20-39 UnitsWeak positive
40-59 UnitsModerate positive
60 Units or GreaterStrong positive

0050639Nuclear Antibody (ANA) by IFA, IgGLess than 1:40

Interpretive Data
Refer to report.

Compliance Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Antibodies: Ro52, Ro60, Jo-1, PL-7, PL12, EJ, Ku, SRP, OJ, PM/Scl-100, MDA5, CCP, Scl-70, RA, ANA, NXP-2
CPT Code(s)
83516 x8; 86235 x5; 86200; 86431; 86039
Components
Component Test Code*Component Chart NameLOINC
0050465Rheumatoid Factor15205-8
0050599Scleroderma (Scl-70) (ENA) Antibody, IgG47322-3
0050639Anti-Nuclear Antibody (ANA), IgG by IFA56634-9
0050691SSA 52 (Ro) (ENA) Antibody, IgG31625-7
0055256Cyclic Citrullinated Peptide Ab, IgG33935-8
0099592Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG14235-6
2003041PM/Scl 100 Antibody, IgG81732-0
2010853PL-7 (threonyl-tRNA synthetase) Antibody33772-5
2010854PL-12 (alanyl-tRNA synthetase) Antibody33771-7
2010856EJ (glycyl-tRNA synthetase) Antibody45149-2
2010857Ku Antibody18484-6
2010859SRP (Signal Recognition Particle) Ab33921-8
2010860OJ (isoleucyl-tRNA synthetase) Antibody45152-6
2012055SSA 60 (Ro) (ENA) Antibody, IgG53019-6
2013963NXP-2 (Nuclear matrix protein-2) Ab82426-8
2013964MDA5 (CADM-140) Antibody82424-3
2013998Interpretive Information48767-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases